EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review

Ameen Nasser iD, Mateusz Michalczak iD, Alexandra Malkowski, Wiktoria Małgorzata Zgoda iD, Jakub Michalczak, Anna Żądło iD, Tomasz Tokarek iD

Journal of Clinical Medicine · 25.07.2026 · 15 (15) · 5832

DOI: 10.3390/jcm15155832 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.07.2026. Verfasst von Ameen Nasser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality. This systematic review evaluates the effects of tafamidis on echocardiographic parameters, cardiac biomarkers, functional outcomes, mortality, and safety in patients with ATTR-CM.

Methods

This systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261391553). PubMed, Embase, and Web of Science were searched through 20 March 2026. Eligible studies included adults with ATTR-CM treated with tafamidis and reporting, echocardiographic, biomarker, functional, mortality, or safety outcomes. Randomized controlled trials and observational studies were included. Risk of bias was assessed using the Cochrane RoB 2 tool and Newcastle–Ottawa Scale. Due to substantial heterogeneity, a narrative synthesis was performed.

Results

Seventeen studies were included with a total of 1890 patients. Tafamidis treatment was potentially associated with stabilization of global longitudinal strain, preservation of functional status, and lower all-cause mortality compared with untreated or control cohorts. Biomarker findings, including N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT), were heterogeneous and did not demonstrate a consistent pattern of improvement. Functional outcomes, including New York Heart Association (NYHA) class, 6-minute walk distance (6MWT), National Amyloidosis Center (NAC) staging, and quality-of-life measures, suggested slower clinical deterioration among treated patients. Limited available safety data indicated that tafamidis was generally well tolerated, with no major safety concerns identified.

Conclusions

Current evidence may suggest that tafamidis slows disease progression and may potentially be associated with improved survival in ATTR-CM. Further prospective studies with standardized outcome reporting are needed. Evidence was limited by heterogeneity in study design, outcome reporting, and follow-up duration, with most included studies being observational.

Schlagwörter

Stichwörter der Autor:innen

NYHA classification scoreall-cause mortalityglobal left ventricular strainleft ventricular ejection fractiontafamidistransthyretin amyloid cardiomyopathy

Autor:innen und Institutionen

  • Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland.
  • Center for Invasive Cardiology, Electrotherapy and Angiology, 33-300 Nowy Sacz, Poland.

ORCID-Profile: Ameen Nasser, Mateusz Michalczak, Wiktoria Małgorzata Zgoda, Anna Żądło, Tomasz Tokarek

Zitieren

APA

Nasser, A., Michalczak, M., Malkowski, A., Zgoda, W. M., Michalczak, J., Żądło, A., & Tokarek, T. (2026). Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review. Journal of Clinical Medicine, 15(15), 5832. https://doi.org/10.3390/jcm15155832

Vancouver

Nasser A, Michalczak M, Malkowski A, Zgoda WM, Michalczak J, Żądło A, et al. Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review. Journal of Clinical Medicine. 2026;15(15):5832. doi:10.3390/jcm15155832

BibTeX
@article{Nasser2026,
  author = {Nasser, Ameen and Michalczak, Mateusz and Malkowski, Alexandra and Zgoda, Wiktoria Małgorzata and Michalczak, Jakub and Żądło, Anna and Tokarek, Tomasz},
  title = {Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {15},
  pages = {5832},
  doi = {10.3390/jcm15155832}
}
Kostenlos starten →